Yu et al. found that mutations in the oncogene Pik3CA lead to glutamine dependence in CRC, suggesting that targeting glutamine metabolism may be an effective treatment for patients with Pik3CA-mutated CRC 18. Here, PIK3CA is linked to colorectal carcinoma.